ArticleBMJ open2024

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.

Liucheng Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.